Your new post is loading...
Scooped by Beeyond
Scoop.it!

Clinical trial of needle-free COVID-19 vaccine underway in Australia

Clinical trial of needle-free COVID-19 vaccine underway in Australia | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Researchers and biotechnology company Vaxxas are studying if the new delivery technology, called a high-density microarray patch, can protect participants from diseases including measles and rubella. If successful, the needle-less technology could be used for a number of other vaccinations including influenza and COVID-19.

No comment yet.
Scooped by Beeyond
Scoop.it!

HIV Patient Sees Coronavirus Mutate 30 Times Over 216 Days

HIV Patient Sees Coronavirus Mutate 30 Times Over 216 Days | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Amongst other variants, the woman was reported to have had the E484K mutation, which is part of the Alpha variant (B.1.1.7, which was first seen in the UK) and the N510Y mutation, which is part of the Beta variant (B.1.351, which was first seen in South Africa). In total, the virus was reported to have undergone 13 mutations to the spike protein and 19 others that could change its behavior.

No comment yet.
Scooped by Beeyond
Scoop.it!

China has 100 million doses of BioNTech COVID vaccine—why hasn’t it approved the jab?

China has 100 million doses of BioNTech COVID vaccine—why hasn’t it approved the jab? | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it
Chinese authorities have yet to approve the COVID-19 vaccine produced by German maker BioNTech and distributed locally by Chinese firm Fosun Pharma. The delay means China can’t access 100 million doses of the proven and effective COVID-19 vaccine it has procured as the country ramps up an ambitious effort to inoculate hundreds of millions of people at home and abroad in coming months.
Beeyond's insight:
Regulatory hurdles and politics may be behind the puzzling delay.
No comment yet.
Scooped by Beeyond
Scoop.it!

80% Of Patients Hospitalized With Covid-19 Develop Neurologic Complications And Are 6 Times More Likely To Die, New Study Finds

80% Of Patients Hospitalized With Covid-19 Develop Neurologic Complications And Are 6 Times More Likely To Die, New Study Finds | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

According to results of a new JAMA Network Open study, 8 in 10 patients hospitalized with Covid-19 developed neurologic complications, with a subsequent sixfold risk of increased mortality. Patients with neurological complications were more likely to die in the hospital compared to patients with no evidence of neurologic involvement, the study also found.

Beeyond's insight:

The study found that having a preexisting neurological condition of any kind -- from brain, spinal cord and nerve diseases to chronic migraines, dementia or Alzheimer's disease, among others -- is the strongest predictor of developing COVID-19-related neurological complications, increasing the risk by two-fold. In addition, having any neurological symptoms related to COVID-19 -- from something as seemingly innocuous as the loss of smell to major events like strokes -- is associated with a six-fold higher risk of dying.

No comment yet.
Scooped by Beeyond
Scoop.it!

L’ARN messager et les nanovecteurs ouvrent la voie vers une nouvelle génération de vaccins d’une efficacité sans égale

L’ARN messager et les nanovecteurs ouvrent la voie vers une nouvelle génération de vaccins d’une efficacité sans égale | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Dans moins de dix ans, cette nouvelle génération de vaccins, dont certains seront universels et efficaces contre toutes les formes du pathogène ciblé, vont permettre à l’Humanité d’accomplir un nouveau pas de géant en matière de prévention et de lutte contre les maladies les plus répandues et plus mortelles. Dans un tel contexte, il est évidemment capital pour notre avenir que la France, pays de Pasteur et de Yercin, jette sans tarder les bases d’un nouveau et puissant pacte de recherche entre sa recherche fondamentale, qui reste au plus niveau, et doit garder un horizon à long terme, et son industrie pharmaceutique, afin de rester dans cette course scientifique et technologique planétaire qui va bouleverser nos vies et nos sociétés.

No comment yet.
Scooped by Beeyond
Scoop.it!

Samsung Biologics to provide fill-finish manufacturing for Moderna COVID vaccine

Samsung Biologics to provide fill-finish manufacturing for Moderna COVID vaccine | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Upon execution of the deal, tech transfer will start immediately and Samsung Biologics will perform aseptic fill-finish, labeling, and packaging services from its Incheon, South Korea site, to support the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine, intended for the supply of markets outside of the US starting in the third quarter of 2021.

No comment yet.
Scooped by Beeyond
Scoop.it!

WHO Approved China's Covid-19 Vaccine for Emergency Use

WHO Approved China's Covid-19 Vaccine for Emergency Use | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

In granting China's Sinopharm emergency use authorization, the vaccine can be included in Covax — which is the WHO's global initiative that aims to realize equitable vaccine distribution worldwide. Several well-off countries aren't sharing as many vaccines as they otherwise might. India is a major developer of vaccines, but has halted exports to better confront its exacerbated coronavirus crisis. Additionally, concerns surrounding the safety of using the AstraZeneca and Johnson & Johnson vaccines — in light of extremely rare but dangerous side effects observed in some countries — and this has led to temporary halts of both vaccines pending additional guidance.

No comment yet.
Scooped by Beeyond
Scoop.it!

MIT: No need to panic about COVID-19 'variants'

MIT: No need to panic about COVID-19 'variants' | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

New variants of the COVID-19 – including a fourth blamed for a surge of infections in India – have raised concerns worldwide that vaccines may be rendered ineffective, restoring lockdowns. The World Health Organization's lead coronavirus adviser, Maria Van Kerkhove, has warned of evidence suggesting variants first identified in the U.K., South Africa and Brazil display "increased transmissibility."
But a prominent virologist cited in an article published by MIT Technology Review affirms the conclusion of other researchers that "the virus hasn't fundamentally changed," reports PJ Media's Stephen Kruiser.

No comment yet.
Scooped by Beeyond
Scoop.it!

'We Could Have Prevented COVID-19,' Says WHO

'We Could Have Prevented COVID-19,' Says WHO | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

The COVID-19 pandemic was and remains a horrible disaster, but it may also have been a preventable one, potentially sparing millions of lives globally, if everyone had reacted more quickly, according to an independent and high-level panel of the World Health Organization initially reported by The Guardian.
We're not here to point fingers, but global leaders could do better to ensure that there is no next time for something like the coronavirus crisis. But we also must be wary of overcorrections, where fundamental losses are forced on the quality of human life for the average citizen.

No comment yet.
Scooped by Beeyond
Scoop.it!

Think out of the box to scale up Covaxin production

Think out of the box to scale up Covaxin production | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

With the Centre decentralising and liberalising their vaccination policy, more than 10 states have decided to float global tenders for foreign Covid jabs to vaccinate its population in the 18-44 age group. That is the category the policy says the Centre will not cover under its free vaccination programme, so the burden of inoculating them for free is on the states. Global shopping began because domestic manufacturers Serum Institute of India (SII) and Bharat Biotech are struggling to meet even the needs of the 45+ group that the Centre is committed to funding for vaccination. The 45+ is the priority group since 85% of all Covid deaths during the first wave happened in that section of the population. But the question is which foreign manufacturer other than Russia’s Sputnik V is prepared to sell at short notice, given the huge back orders they already have from the global North.

No comment yet.
Scooped by Beeyond
Scoop.it!

GOA Chose to Think Out of the Box to Tell Its People to Stay the F*** At Home

GOA Chose to Think Out of the Box to Tell Its People to Stay the F*** At Home | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Despite numerous warnings, people fail to understand the gravity of the situation and choose to stay out of their homes for no valid reason. Our country is undoubtedly in the midst of a crisis. The number of people that are getting affected by the virus is increasing with every passing day. And, yet, we find people roaming carelessly on streets and not abiding by the basic rules.

No comment yet.
Scooped by Beeyond
Scoop.it!

SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties

SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

We compared COVID-19 deaths, gross domestic product (GDP) growth, and strictness of lockdown measures during the first 12 months of the pandemic for Organisation for Economic Co-operation and Development (OECD) countries that aim for elimination or mitigation (figure). Although all indicators favour elimination, our analysis does not prove a causal connection between varying pandemic response strategies and the different outcome measures. COVID-19 deaths per 1 million population in OECD countries that opted for elimination (Australia, Iceland, Japan, New Zealand, and South Korea) have been about 25 times lower than in other OECD countries that favoured mitigation (figure). Mortality is a proxy for a country's broader disease burden. For example, decision makers should also consider the increasing evidence of long-term morbidities after SARS-CoV-2 infection.

No comment yet.
Scooped by Beeyond
Scoop.it!

Genetic Mutation of SARS-CoV-2 during Consecutive Passages in Permissive Cells

Genetic Mutation of SARS-CoV-2 during Consecutive Passages in Permissive Cells | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

The spike glycoprotein of SARS-CoV-2 is more likely to mutate during in vitro passage, which is consistent with the reported outcomes of person-to-person transmission (Gong et al. 2020). It remains largely unknown whether mutations acquired during in vitro passages additionally affect viral intrinsic characteristics. Continuous monitoring of SARS-CoV-2 could benefit not only biological studies of this virus but also vaccine development in the future.

No comment yet.
Scooped by Beeyond
Scoop.it!

Wastewater Transmission of SARS-CoV-2 Isn’t Driving the Pandemic

Wastewater Transmission of SARS-CoV-2 Isn’t Driving the Pandemic | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Infectious SARS-CoV-2 has been isolated from the stool of a few COVID-19 patients worldwide. However, there are not yet published reports of infectious SARS-CoV-2 isolation from wastewater. While fecal-oral transmission via wastewater has been hypothesized, the empirical evidence indicates the probability is quite low. The basis for this assertion is summarized in the commentary “Differentiating between the possibility and probability of SARS-CoV-2 transmission associated with wastewater: empirical evidence is needed to substantiate risk” published in FEMS Microbes. Two authors of the study, Aaron Bivins and Warish Ahmed, discuss for the #FEMSmicroBlog how we need to remain focused on airborne transmission via respiratory shedding until empirical evidence establishes otherwise. #FascinatingMicrobes

No comment yet.
Scooped by Beeyond
Scoop.it!

Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?

Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2? | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

It is increasingly clear that transmission of SARS-CoV-2 via aerosol is possible and might represent a significant transmission route. However, emerging evidence indicates that many currently defined AGPs are unlikely to play any significant role in generation of infectious aerosol that poses a risk to staff. In view of this, the term AGP has neither face validity nor construct validity. Instead, we should focus on the risk in plain sight: close, physical exposure to people suspected, or known to have, COVID-19 for prolonged time or where ventilation remains poor.

No comment yet.
Scooped by Beeyond
Scoop.it!

The role of ventilation in preventing the transmission of SARS-CoV-2

The role of ventilation in preventing the transmission of SARS-CoV-2 | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Respiratory viruses are versatile beasts, able to spread by all of the key transmission routes under some circumstances: contact (including indirect contact spread via surfaces), droplet, and airborne routes. This is true of influenza, SARS-CoV-1, SARS-CoV-2 and many others. I wrote a review paper in 2016 reviewing the evidence for the role of contaminated surfaces in the transmission of respiratory viruses. The image below is from that review (dated 2016). I think it’s still helpful to illustrate the various transmission routes for respiratory viruses, but the definitions of “droplets” and “droplet nuclei” now seem rather dated.

No comment yet.
Scooped by Beeyond
Scoop.it!

Asymptomatic pediatric dental patients as potential SARS-CoV-2 carriers

Asymptomatic pediatric dental patients as potential SARS-CoV-2 carriers | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

In a recent study, researchers have examined the prevalence of COVID-19 in pediatric dentistry by testing children during their visit at the pediatric dentist’s office. The study reported that, although all the children who took part in the study were asymptomatic, some of them tested positive after undergoing polymerase chain reaction (PCR) tests. This suggests that testing pediatric dental patients could help better identify potential SARS-CoV-2 carriers and subsequently reduce transmission rates.

No comment yet.
Scooped by Beeyond
Scoop.it!

How did SARS-CoV-2 first evolve in humans?

How did SARS-CoV-2 first evolve in humans? | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

The spike glycoprotein on the viral envelope is the main entry protein of SARS-CoV-2 that initiates viral entry into human cells. Upon binding to the angiotensin-converting enzyme 2 (ACE2) receptor on the human cell membrane, the spike protein undergoes a series of conformational changes, which collectively result in viral entry and infection establishment.

No comment yet.
Scooped by Beeyond
Scoop.it!

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion

Indian SARS-CoV-2 variant shows enhanced host cell entry and immune evasion | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

A study conducted by researchers in Germany has found that the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has emerged in India entered certain types of lung and intestine cells with slightly increased efficiency compared with the original wild-type strain. The B.1.617 variant is the lineage thought to be responsible for the sharp rise in coronavirus disease 2019 (COVID-19) cases and deaths in India over recent weeks.

No comment yet.
Scooped by Beeyond
Scoop.it!

Researchers study SARS-CoV-2 antibodies in asymptomatic and symptomatic individuals

Researchers study SARS-CoV-2 antibodies in asymptomatic and symptomatic individuals | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

MUSC Hollings Cancer Center researchers added to the understanding of the protective immune response against the SARS-CoV-2 virus in a study published in April in iScience. The team found that approximately 3% of the population is asymptomatic, which means that their bodies can get rid of the virus without developing signs of illness.

No comment yet.
Scooped by Beeyond
Scoop.it!

COVID-19 vaccine is associated with fewer asymptomatic SARS-CoV-2 infections

COVID-19 vaccine is associated with fewer asymptomatic SARS-CoV-2 infections | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

The study is among the first to show an association between COVID-19 vaccination and fewer asymptomatic infections. When the Pfizer-BioNTech BNT162b2 vaccine was authorized for use in the U.S., the vaccine was reported to be highly effective at preventing laboratory-confirmed COVID-19. Clinical trial data suggested that the two-dose regimen reduced symptomatic disease, including hospitalization and death. But an association with reduced asymptomatic infection was unclear.

No comment yet.
Scooped by Beeyond
Scoop.it!

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Highly efficient immune response in asymptomatic SARS-CoV-2 patients | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

Researchers in Singapore have investigated the role of SARS-CoV-2-specific antibodies and T-cells in asymptomatic individuals suffering from COVID-19. They found that, contrary to some initial hypotheses, asymptomatic individuals mount an adaptive immune response on par with symptomatic individuals, demonstrating that T cell response does not appear to be correlated with symptom severity.

No comment yet.
Scooped by Beeyond
Scoop.it!

Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues

Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

An unresolved issue of SARS-CoV-2 disease is that patients often remain positive for viral RNA as detected by PCR many weeks after the initial infection in the absence of evidence for viral replication. We show here that SARS-CoV-2 RNA can be reverse-transcribed and integrated into the genome of the infected cell and be expressed as chimeric transcripts fusing viral with cellular sequences. Importantly, such chimeric transcripts are detected in patient-derived tissues. Our data suggest that, in some patient tissues, the majority of all viral transcripts are derived from integrated sequences. Our data provide an insight into the consequence of SARS-CoV-2 infections that may help to explain why patients can continue to produce viral RNA after recovery.

Beeyond's insight:

The real question is whether the cell culture data have any relevance to human health or diagnostics. “In the absence of evidence of integration in patients, the most I can take away from these data is that it is possible to detect SARS-CoV-2 RNA retroposition events in infected cell lines where L1 is overexpressed,” Feschotte says. “The clinical or biological significance of these observations, if any, is a matter of pure speculation at this point.”

No comment yet.
Scooped by Beeyond
Scoop.it!

Further evidence supports controversial claim that SARS-CoV-2 genes can integrate with human DNA

Further evidence supports controversial claim that SARS-CoV-2 genes can integrate with human DNA | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

A team of prominent scientists has doubled down on its controversial hypothesis that genetic bits of the pandemic coronavirus can integrate into our chromosomes and stick around long after the infection is over. If they are right—skeptics have argued that their results are likely lab artifacts—the insertions could explain the rare finding that people can recover from COVID-19 but then test positive for SARS-CoV-2 again months later.

Beeyond's insight:

“The integration data in cell culture is much more convincing than what was presented in the preprint, but it’s still not totally clean,” says Feschotte, who now calls Jaenisch’s and Young’s hypothesis “plausible.” (SARS-CoV-2, he notes, can also persist in a person for months without integrating its genes.)

The real question is whether the cell culture data have any relevance to human health or diagnostics. “In the absence of evidence of integration in patients, the most I can take away from these data is that it is possible to detect SARS-CoV-2 RNA retroposition events in infected cell lines where L1 is overexpressed,” Feschotte says. “The clinical or biological significance of these observations, if any, is a matter of pure speculation at this point.”

No comment yet.
Scooped by Beeyond
Scoop.it!

SARS-CoV-2 RNA can be reverse-transcribed

SARS-CoV-2 RNA can be reverse-transcribed | Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz | Scoop.it

A study appearing as a preprint on the bioRxiv* server in December 2020 reveals that the genome of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is inserted into the human genome, accounting for the detection of viral RNAs, even in late convalescence.

No comment yet.
Curated by Beeyond
BEEYOND is a consulting company in the field of disruptive innovation, accompanying established companies on out-of-the-core growth strategy, from creation of new concepts to product launch. Reach us at: contact@beeyond.fr.